Avita Medical Ltd (RCEL) - Total Liabilities

Latest as of December 2025: $73.04 Million USD

Based on the latest financial reports, Avita Medical Ltd (RCEL) has total liabilities worth $73.04 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Avita Medical Ltd - Total Liabilities Trend (1993–2025)

This chart illustrates how Avita Medical Ltd's total liabilities have evolved over time, based on quarterly financial data. See Avita Medical Ltd (RCEL) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Avita Medical Ltd Competitors by Total Liabilities

The table below lists competitors of Avita Medical Ltd ranked by their total liabilities.

Company Country Total Liabilities
SENFONG
KLSE:5308
Malaysia RM214.06 Million
RumbleON Inc
NASDAQ:RMBL
USA $717.00 Million
Taiwan Fructose Co Ltd
TWO:4207
Taiwan NT$2.13 Billion
Indonesia Fibreboard Industry PT
JK:IFII
Indonesia Rp402.69 Billion
Yellow Pages Limited
TO:Y
Canada CA$110.75 Million
Minaurum Silver Inc.
V:MGG
Canada CA$1.43 Million
Health Catalyst Inc
NASDAQ:HCAT
USA $274.06 Million
Awardit AB
ST:AWRD
Sweden Skr636.19 Million

Liability Composition Analysis (1993–2025)

This chart breaks down Avita Medical Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RCEL market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.57 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -4.39 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Avita Medical Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Avita Medical Ltd (1993–2025)

The table below shows the annual total liabilities of Avita Medical Ltd from 1993 to 2025.

Year Total Liabilities Change
2025-12-31 $73.04 Million -2.89%
2024-12-31 $75.21 Million +20.18%
2023-12-31 $62.58 Million +362.76%
2022-12-31 $13.52 Million +18.73%
2021-12-31 $11.39 Million +13.22%
2020-12-31 $10.06 Million +103.17%
2019-12-31 $4.95 Million +23.34%
2017-12-31 $4.01 Million +57.68%
2016-12-31 $2.55 Million +45.46%
2015-12-31 $1.75 Million +42.74%
2014-12-31 $1.23 Million -31.35%
2013-12-31 $1.79 Million -27.19%
2012-12-31 $2.45 Million +14.00%
2011-12-31 $2.15 Million +26.54%
2010-12-31 $1.70 Million -56.17%
2009-12-31 $3.88 Million +287.84%
2008-12-31 $1.00 Million -60.72%
2007-12-31 $2.55 Million +138.67%
2006-12-31 $1.07 Million -44.69%
2005-12-31 $1.93 Million +38.67%
2004-12-31 $1.39 Million +172.15%
2003-12-31 $511.27K +63.12%
2002-12-31 $313.44K -40.36%
2001-12-31 $525.57K +1351.65%
2000-12-31 $36.21K -58.71%
1999-12-31 $87.69K +342.35%
1998-12-31 $19.82K +4.35%
1997-12-31 $19.00K -61.80%
1996-12-31 $49.74K -41.90%
1995-12-31 $85.60K -64.52%
1994-12-31 $241.24K -36.85%
1993-12-31 $381.99K --

About Avita Medical Ltd

NASDAQ:RCEL USA Medical Devices
Market Cap
$121.26 Million
Market Cap Rank
#18566 Global
#4247 in USA
Share Price
$3.94
Change (1 day)
+0.51%
52-Week Range
$3.27 - $6.76
All Time High
$55.20
About

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitili… Read more